These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1064685)

  • 1. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
    Gailani S; Nussbaum A
    J Med; 1976; 7(2):93-102. PubMed ID: 1064685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
    Mejer J
    Scand J Clin Lab Invest; 1982 Sep; 42(5):401-6. PubMed ID: 6961505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL; Rustum YM
    Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia.
    Zittoun R; Zittoun J; Marquet J; Rustum Y; Creaven P
    Cancer Res; 1985 Oct; 45(10):5186-92. PubMed ID: 4027995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Results of therapy with high-dose cytosine arabinoside].
    Pralle H; Breithaupt H
    Onkologie; 1985 Feb; 8(1):48, 50-2. PubMed ID: 3885122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
    Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
    Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
    Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
    Vaughan WP; Burke PJ
    Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of the malignancies from the viewpoint of pharmacology and biochemistry of cytosine arabinoside (ara-C) and its derivatives].
    Nakamura T; Ueda T
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1339-51. PubMed ID: 6191711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.